PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 1992The Journal of Experimental Medicine160 citationsOpen Access

Anti-CD4 abrogates rejection and reestablishes long-term tolerance to syngeneic newborn hearts grafted in mice chronically infected with Trypanosoma cruzi.

RSRicardo Ribeiro dos SantosMRMarcos A. RossiJLJ.L. Laus

Structured PICO

Does anti-CD4 monoclonal antibody treatment prevent rejection of syngeneic heart grafts in mice chronically infected with Trypanosoma cruzi?

P
Population
BALB/c mice chronically infected with Trypanosoma cruzi receiving syngeneic newborn heart grafts
I
Intervention
In vivo treatment with anti-CD4 monoclonal antibodies
C
Comparator
Anti-CD8 monoclonal antibodies
O
Outcome
Rejection of syngeneic newborn heart grafts

Anti-CD4 treatment prevents syngeneic heart graft rejection in T. cruzi-infected mice, suggesting autoimmunity driven by CD4+ T cells is a major mechanism in Chagasic cardiomyopathy.

Abstract

The contribution of autoimmunity in the genesis of chronic Chagas' heart pathology is not clear. In the present study, we show that: (a) BALB/c mice chronically infected with Trypanosoma cruzi reject syngeneic newborn hearts; (b) in vivo treatment with anti-CD4 but not anti-CD8 monoclonal antibodies (mAbs) abrogates rejection; (c) CD4+ T cells from chronically infected mice proliferate in vitro to syngeneic myocardium antigens and induce heart graft destruction when injected in situ; (d) anti-CD4 treatment of chronically infected mice establishes long-term tolerance to syngeneic heart grafts; and (e) the state of tolerance is related to in vitro and in vivo unresponsiveness of the CD4+ T cells. These findings allow us to suggest that autoimmunity is the major mechanism implicated in the rejection of syngeneic heart tissues grafted into the pinna of the ear of mice chronically infected with T. cruzi. The similarity of the lesions to those found in humans suggests that autoimmunity is involved in the pathogenesis of chagasic cardiomyopathy in humans. Moreover, this could imply therapeutic strategies by reestablishing long-term tissue-specific tolerance with anti-CD4 mAb treatment, mediating anergy, or deleting the responder CD4+ T cells to heart tissue antigens.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Santos et al. (1992) studied this question.

synapsesocial.com/papers/6a9288bb6a4f73282e182b66https://doi.org/10.1084/jem.175.1.29
Ask AI
Helpful
Bookmark
Share
View Full Paper